<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003942</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067135</org_study_id>
    <secondary_id>SYSTEMIX-105</secondary_id>
    <secondary_id>UCLA-HSPC-980303601D</secondary_id>
    <secondary_id>NCI-G99-1549</secondary_id>
    <nct_id>NCT00003942</nct_id>
  </id_info>
  <brief_title>Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase I/II Study of the Safety and Feasibility of REVM10 or REVM10/ANTISENSE POL 1 Transduced Hematopoietic Stem Cells (HSC) in HIV-1 Related Non-Hodgkin's Lymphoma Patients Already Being Treated With High Dose Chemotherapy and Peripheral Blood Stem Cell Support</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Systemix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Inserting the gene for RevM10 into a person's peripheral stem cells may improve&#xD;
      the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of RevM10-treated stem cells plus&#xD;
      chemotherapy and peripheral stem cell transplantation in treating patients who have&#xD;
      HIV-related non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the safety of infusion of RevM10 or RevM10/polAS transduced&#xD;
      hematopoietic stem cells (HSC) in addition to high dose chemotherapy and standard peripheral&#xD;
      blood stem cell support in patients with HIV-1 related non-Hodgkin's lymphoma. II. Determine&#xD;
      gene marking of lymphocytes and myeloid cells in peripheral blood, bone marrow, and/or lymph&#xD;
      nodes after infusion of RevM10-HSC or RevM10/polAS-HSC in these patients. III. Determine the&#xD;
      antiretroviral effect of this treatment in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients receive mobilization therapy and undergo&#xD;
      leukapheresis according to a standard protocol. High dose chemotherapy is administered on&#xD;
      days -7 to -1, also according to a standard protocol. On day 0, autologous hematopoietic stem&#xD;
      cells transduced with genes RevM10 or RevM10/polAS are infused. Unmodified autologous&#xD;
      peripheral blood stem cells are reinfused on day 1. Patients are followed daily for 2 weeks,&#xD;
      weekly for 2 weeks, monthly for 1 year, then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 15 patients will be accrued for this study within 14 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 1998</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RevM10 gene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RevM10/polAS gene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: HIV-1 infection documented by ELISA and Western blot&#xD;
        Histologically proven non-Hodgkin's lymphoma showing at least partial response to standard&#xD;
        chemotherapy regimen Poor prognosis in first chemotherapy induced remission Increased LDH&#xD;
        AND/OR Stage III or IV AND/OR Reduced performance status (ECOG 2 or worse) OR Response but&#xD;
        no complete remission following four courses of standard chemotherapy OR Responding relapse&#xD;
        after primary therapy No primary CNS lymphoma No uncontrolled meningeal lymphoma at&#xD;
        mobilization&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: See Disease Characteristics&#xD;
        Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1500/mm3&#xD;
        Platelet count at least 100,000/mm3 CD4 count at least 100/mm3 Hepatic: Bilirubin less than&#xD;
        2 mg/dL (unless taking indinavir) SGOT and SGPT less than 2 times normal No hepatitis&#xD;
        Renal: Creatinine less than 2.0 mg/dL Pulmonary: DLCO greater than 60% Other: Not pregnant&#xD;
        or nursing Fertile patients must use effective contraception No active Mycobacterium&#xD;
        avium-intracellulare infection or CMV disease No cerebral toxoplasmosis or cryptococcal&#xD;
        meningitis At least 6 months since prior alcohol or substance abuse At least 1 year since&#xD;
        CNS disease or seizures No other medical condition that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease&#xD;
        Characteristics No concurrent chemotherapy for Kaposi's sarcoma Endocrine therapy: Not&#xD;
        specified Radiotherapy: Not specified Surgery: Not specified Other: At least 30 days since&#xD;
        prior treatment for serious opportunistic infections&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tyler Martin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Systemix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Oncology</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2000</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2004</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related diffuse large cell lymphoma</keyword>
  <keyword>AIDS-related immunoblastic large cell lymphoma</keyword>
  <keyword>AIDS-related small noncleaved cell lymphoma</keyword>
  <keyword>AIDS-related diffuse mixed cell lymphoma</keyword>
  <keyword>AIDS-related diffuse small cleaved cell lymphoma</keyword>
  <keyword>AIDS-related lymphoblastic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

